计算溶液所需的质量、体积或浓度。
This is a demo store. No orders will be fulfilled.
| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| A127600-5mg |
5mg |
现货 ![]() |
| |
| A127600-25mg |
25mg |
现货 ![]() |
| |
| A127600-100mg |
100mg |
现货 ![]() |
|
| 英文别名 | AKOS024464879 | i-butanal | BDBM50429701 | D10887 | NCGC00346698-12 | Butanone 2 [French] | J-000268 | SMR004702809 | VISTUSERTIB [WHO-DD] | 3-[2,4-Bis-[(3S)-3-methyl-4-morpholinyl]-pyrido[2,3-d]pyrimidin-7-yl]-N-methylbenzamide | 3-[2,4-Bis[(3S)-3-methyl |
|---|---|
| 规格或纯度 | Moligand™, ≥98% |
| 英文名称 | AZD2014 |
| 生化机理 | mTOR 激酶抑制剂 AZD2014 可抑制 mTOR 的活性,从而诱导肿瘤细胞凋亡并减少肿瘤细胞增殖。mTOR是一种在多种肿瘤中上调的丝氨酸/苏氨酸激酶,在PI3K/Akt/mTOR信号通路的下游发挥重要作用。对多(xa0PI3K)(xa0)异构体具有高度选择性。还能靶向 P-Akt(IC 50 = 80 nM)和 pS6(IC 50 = 200 nM)。一种具有潜在抗肿瘤活性的口服抑制剂 |
| 储存温度 | -20°C储存 |
| 运输条件 | 超低温冰袋运输 |
| 作用类型 | 抑制剂 |
| 作用机制 | 丝氨酸/苏氨酸蛋白激酶 mTOR 抑制剂 |
| 备注 | 有毒,请参阅SDS以获取更多信息。需要更多关于溶解度,用法和处理的建议吗?请访问我们的常见问题(FAQ)页面以获取更多详细信息。 |
| 产品介绍 |
AZD2014是高效mTOR抑制剂,IC50为2.8 nM,对PI3K各亚型(α/β/γ/δ)的抑制性较弱。A selective inhibitor of mTOR kinase AZD2014 is a novel mTOR inhibitor with IC50 of 2.8 nM; highly selective against multiple PI3K isoforms (α/β/γ/δ). |
| 纯度 | ≥98% |
| ALogP | 2.8 |
|---|
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|
| PubChem SID | 504770044 |
|---|---|
| 分子类型 | 小分子 |
| IIUPAC Name | 3-[2,4-bis[(3S)-3-methylmorpholin-4-yl]pyrido[2,3-d]pyrimidin-7-yl]-N-methylbenzamide |
| INCHI | 1S/C25H30N6O3/c1-16-14-33-11-9-30(16)23-20-7-8-21(18-5-4-6-19(13-18)24(32)26-3)27-22(20)28-25(29-23)31-10-12-34-15-17(31)2/h4-8,13,16-17H,9-12,14-15H2,1-3H3,(H,26,32)/t16-,17-/m0/s1 |
| InChi Key | JUSFANSTBFGBAF-IRXDYDNUSA-N |
| Smiles | CC1COCCN1C2=NC(=NC3=C2C=CC(=N3)C4=CC(=CC=C4)C(=O)NC)N5CCOCC5C |
| Isomeric SMILES | C[C@H]1COCCN1C2=NC(=NC3=C2C=CC(=N3)C4=CC(=CC=C4)C(=O)NC)N5CCOC[C@@H]5C |
| 分子量 | 462.54 |
| Reaxy-Rn | 26042180 |
| Reaxys-RN link address | https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN=26042180&ln= |
| 溶解性 | DMSO 38 mg/mL Water <1 mg/mL Ethanol <1 mg/mL |
|---|---|
| 密度 | 1.2 |
| 折光率 | 1.61 |
| 分子量 | 462.500 g/mol |
| XLogP3 | 2.800 |
| 氢键供体数Hydrogen Bond Donor Count | 1 |
| 氢键受体数Hydrogen Bond Acceptor Count | 8 |
| 可旋转键计数Rotatable Bond Count | 4 |
| 精确质量Exact Mass | 462.238 Da |
| 单同位素质量Monoisotopic Mass | 462.238 Da |
| 拓扑极表面积Topological Polar Surface Area | 92.700 Ų |
| 重原子数Heavy Atom Count | 34 |
| 形式电荷Formal Charge | 0 |
| 复杂度Complexity | 698.000 |
| 同位素原子数Isotope Atom Count | 0 |
| 定义的原子立体中心计数Defined Atom Stereocenter Count | 2 |
| 未定义的原子立体中心计数Undefined Atom Stereocenter Count | 0 |
| 定义的键立体中心计数Defined Bond Stereocenter Count | 0 |
| 未定义的键立体中心计数Undefined Bond Stereocenter Count | 0 |
| 所有立体化学键的总数The total count of all stereochemical bonds | 0 |
| 共价键合单元计数Covalently-Bonded Unit Count | 1 |
| 象形图 | GHS06, GHS08 |
|---|---|
| 信号词 | 危险 |
| 危险声明 |
H301: 吞咽会中毒 H360: 可能损害生育力或未出生的孩子 H373: 通过长时间或反复暴露对器官造成损害 |
| 预防措施声明 |
P260: 不要吸入灰尘/烟雾/气体/雾/蒸汽/喷雾。 P264: 处理后要彻底洗手。 P270: 使用本产品时,请勿进食、饮水或吸烟。 P280: 戴防护手套/穿防护服/戴防护眼罩/戴防护面具。 P321: 特殊处理(请参阅此标签上的...)。 P330: 漱口 P405: 密闭存放 P501: 将内容物/容器处理到。。。 P203: 使用前,获取、阅读并遵守所有安全说明。 P301+P316: 如果吞咽:立即寻求紧急医疗救助。 P318: 如果暴露或担心,请就医。 P319: 如果你感到不适,请寻求医疗帮助。 |
| 1. Fabrizio P, Pozza F, Pletcher SD, Gendron CM, Longo VD. (2001) Regulation of longevity and stress resistance by Sch9 in yeast.. Science, 292 (5515): (288-90). [PMID:11292860] |
| 2. Sarbassov DD, Ali SM, Kim DH, Guertin DA, Latek RR, Erdjument-Bromage H, Tempst P, Sabatini DM. (2004) Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton.. Curr Biol, 14 (14): (1296-302). [PMID:15268862] |
| 3. Harrison DE, Strong R, Sharp ZD, Nelson JF, Astle CM, Flurkey K, Nadon NL, Wilkinson JE, Frenkel K, Carter CS et al.. (2009) Rapamycin fed late in life extends lifespan in genetically heterogeneous mice.. Nature, 460 (7253): (392-5). [PMID:19587680] |
| 4. Yang Z, Klionsky DJ. (2010) Mammalian autophagy: core molecular machinery and signaling regulation.. Curr Opin Cell Biol, 22 (2): (124-31). [PMID:20034776] |
| 5. Robida-Stubbs S, Glover-Cutter K, Lamming DW, Mizunuma M, Narasimhan SD, Neumann-Haefelin E, Sabatini DM, Blackwell TK. (2012) TOR signaling and rapamycin influence longevity by regulating SKN-1/Nrf and DAF-16/FoxO.. Cell Metab, 15 (5): (713-24). [PMID:22560223] |
| 6. Pike KG, Malagu K, Hummersone MG, Menear KA, Duggan HM, Gomez S, Martin NM, Ruston L, Pass SL, Pass M. (2013) Optimization of potent and selective dual mTORC1 and mTORC2 inhibitors: the discovery of AZD8055 and AZD2014.. Bioorg Med Chem Lett, 23 (5): (1212-6). [PMID:23375793] |
| 7. Datan E, Shirazian A, Benjamin S, Matassov D, Tinari A, Malorni W, Lockshin RA, Garcia-Sastre A, Zakeri Z. (2014) mTOR/p70S6K signaling distinguishes routine, maintenance-level autophagy from autophagic cell death during influenza A infection.. Virology, 452-453 (175-90). [PMID:24606695] |
| 8. Wong Te Fong AC, Thavasu P, Gagrica S, Swales KE, Leach MO, Cosulich SC, Chung YL, Banerji U. (2017) Evaluation of the combination of the dual m-TORC1/2 inhibitor vistusertib (AZD2014) and paclitaxel in ovarian cancer models.. Oncotarget, 8 (69): (113874-113884). [PMID:29371953] |
| 9. Basu B, Krebs MG, Sundar R, Wilson RH, Spicer J, Jones R, Brada M, Talbot DC, Steele N, Ingles Garces AH et al.. (2018) Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high-grade serous ovarian and squamous non-small-cell lung cancer.. Ann Oncol, 29 (9): (1918-1925). [PMID:30016392] |